Study in patients with primary Sjögren’s syndrome with the aim to assess safety, tolerability, pharmacokinetics (way the body absorbs, distributes, and gets rid of the drug) and preliminary efficacy of CDZ173
- Registry ID
- EUCTR2014-004616-12
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Novartis Pharma Services AG
- Start date
- 2016-11-21
- Completion date
- 2017-05-17
- Last update
- 2026-08-16
Conditions
- Primary Sjögren's syndrome
Summary
• To assess the safety and tolerability of CDZ173 in patients with primary Sjögren’s syndrome.
• To compare the effect of CDZ173 versus placebo on the patient-reported outcomes of primary Sjögren’s syndrome patients after 12 weeks of treatment (study week 13).
Locations
- , , Hungary
- , , Germany
- , , Poland
View on source registry